help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tauchmanovà, L.
Right arrow Articles by Selleri, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tauchmanovà, L.
Right arrow Articles by Selleri, C.
The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 11 5058-5065
Copyright © 2002 by The Endocrine Society


Original Article

Long-Lasting Bone Damage Detected by Dual-Energy X-Ray Absorptiometry, Phalangeal Osteosonogrammetry, and in Vitro Growth of Marrow Stromal Cells after Allogeneic Stem Cell Transplantation

Libuse Tauchmanovà, Bianca Serio, Antonio Del Puente, Antonio Maria Risitano, Antonella Esposito, Gennaro De Rosa, Gaetano Lombardi, Annamaria Colao, Bruno Rotoli and Carmine Selleri

Department of Endocrinology (L.T., G.L., A.C.) and Divisions of Rheumatology (A.D.P., A.E.) and Hematology (B.S., A.M.R., G.D.R., B.R., C.S.), Federico II University of Naples, 80131 Naples, Italy

Address all correspondence and requests for reprints to: Carmine Selleri, M.D., Division of Hematology, Federico II University, Via S. Pansini 5, 80131 Napoli, Italy. E-mail: selleri{at}unina.it.

Abstract

Bone complications after allogeneic stem cell transplant (allo-SCT) include osteoporosis, fractures, and osteonecrosis. We investigated bone abnormalities in long-term survivors after busulfan cyclophosphamide-conditioning regimen, followed by human leukocyte antigen-identical sibling SCT. Bone density was measured by dual-energy x-ray absorptiometry at lumbar spine (LS) and femoral neck (FN) and phalangeal osteosonogrammetry (OSG) in 41 patients 1–10 yr after allo-SCT. Using colony-forming units-fibroblast (CFU-F) assay, we analyzed the repopulating capacity of clonogenic fibroblast progenitors belonging to the osteogenic stromal lineage. LS and FN bone mineral density (BMD) and phalangeal densitometric values were significantly reduced, compared with 188 healthy controls (P < 0.001). Decrease in T-score less than 1 SD was documented in 29% and 52% of patients at the LS and FN, respectively. OSG detected densitometric values with a T-score less than 1 SD in 68% of transplanted patients. The patients examined within the first 3 yr after transplant showed low BMD, which remained stable at FN and improved at LS. Phalangeal densitometry was low up to 10 yr after transplant. CFU-F was found permanently depressed and unable to give rise to a confluent stroma. Low serum osteocalcin levels were present throughout the whole follow-up period. A significant correlation was found between densitometric values detected by both techniques and CFU-F growth in vitro. Osteonecrosis was associated with lower FN BMD, and phalangeal densitometry correlated inversely with duration of amenorrhea and chronic graft vs. host disease requiring long-lasting steroid therapy. In conclusion, dual-energy x-ray absorptiometry and phalangeal OSG may provide complementary information on bone density after allo-SCT. Prolonged severe impairment of femoral BMD and phalangeal densitometry suggest that bone loss may persist for many years after transplant. Inability to regenerate a normal number of osteoblastic precursors in the stromal stem cell compartment may in part account for severe long-lasting posttransplant decrease in bone mass.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
L. Tauchmanova, A. Colao, G. Lombardi, B. Rotoli, and C. Selleri
REVIEW: Bone Loss and Its Management in Long-Term Survivors from Allogeneic Stem Cell Transplantation
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4536 - 4545.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Petryk, T. L. Bergemann, K. M. Polga, K. J. Ulrich, S. K. Raatz, D. M. Brown, L. L. Robison, and K. S. Baker
Prospective Study of Changes in Bone Mineral Density and Turnover in Children after Hematopoietic Cell Transplantation
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 899 - 905.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. L. Syrjala, S. L. Langer, J. R. Abrams, B. E. Storer, and P. J. Martin
Late Effects of Hematopoietic Cell Transplantation Among 10-Year Adult Survivors Compared With Case-Matched Controls
J. Clin. Oncol., September 20, 2005; 23(27): 6596 - 6606.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Kananen, L. Volin, K. Laitinen, H. Alfthan, T. Ruutu, and M. J. Valimaki
Prevention of Bone Loss after Allogeneic Stem Cell Transplantation by Calcium, Vitamin D, and Sex Hormone Replacement with or without Pamidronate
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3877 - 3885.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Tauchmanova, P. Ricci, B. Serio, G. Lombardi, A. Colao, B. Rotoli, and C. Selleri
Short-Term Zoledronic Acid Treatment Increases Bone Mineral Density and Marrow Clonogenic Fibroblast Progenitors after Allogeneic Stem Cell Transplantation
J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 627 - 634.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society